Credit Suisse Group reissued their neutral rating on shares of Alder Biopharmaceuticals (NASDAQ:ALDR) in a research note issued to investors on Wednesday, Briefing.com Automated Import reports.
Several other analysts have also weighed in on ALDR. Cowen set a $150.00 target price on Tesla and gave the company a sell rating in a report on Friday, May 3rd. Svb Leerink started coverage on Alder Biopharmaceuticals in a report on Tuesday, May 28th. They issued an outperform rating on the stock. Cantor Fitzgerald reissued a buy rating and issued a $25.00 target price on shares of Menlo Therapeutics in a report on Thursday, May 2nd. Leerink Swann initiated coverage on Alder Biopharmaceuticals in a report on Tuesday, May 28th. They issued an outperform rating and a $21.00 target price on the stock. Finally, Mizuho set a $100.00 price objective on PRA Health Sciences and gave the company a hold rating in a research report on Friday, May 3rd. Two analysts have rated the stock with a sell rating, three have issued a hold rating and ten have assigned a buy rating to the company’s stock. Alder Biopharmaceuticals currently has a consensus rating of Buy and a consensus target price of $19.82.
Alder Biopharmaceuticals stock opened at $11.45 on Wednesday. The company has a current ratio of 8.34, a quick ratio of 8.34 and a debt-to-equity ratio of 1.21. Alder Biopharmaceuticals has a fifty-two week low of $9.44 and a fifty-two week high of $20.87. The firm has a fifty day moving average price of $11.46.
Alder Biopharmaceuticals (NASDAQ:ALDR) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.63) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.16) by ($0.47). Equities analysts predict that Alder Biopharmaceuticals will post -4.43 EPS for the current year.
In related news, EVP James B. Bucher sold 1,897 shares of the stock in a transaction dated Thursday, April 25th. The stock was sold at an average price of $13.85, for a total transaction of $26,273.45. Following the transaction, the executive vice president now directly owns 11,706 shares in the company, valued at $162,128.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 15.40% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. Empire Life Investments Inc. acquired a new stake in shares of Alder Biopharmaceuticals in the first quarter valued at about $130,000. Stifel Financial Corp acquired a new stake in shares of Alder Biopharmaceuticals in the fourth quarter valued at about $154,000. Hsbc Holdings PLC acquired a new stake in shares of Alder Biopharmaceuticals in the fourth quarter valued at about $176,000. LPL Financial LLC grew its stake in shares of Alder Biopharmaceuticals by 43.4% in the fourth quarter. LPL Financial LLC now owns 18,175 shares of the biopharmaceutical company’s stock valued at $186,000 after buying an additional 5,500 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY grew its stake in shares of Alder Biopharmaceuticals by 374.7% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 21,517 shares of the biopharmaceutical company’s stock valued at $221,000 after buying an additional 16,984 shares in the last quarter.
Alder Biopharmaceuticals Company Profile
Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine.
Further Reading: Day Trading
Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.